Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
about
Axitinib for the management of metastatic renal cell carcinomaAxitinib in the treatment of renal cell carcinoma: patient selection and perspectivesAxitinib in Metastatic Renal Cell CarcinomaRisk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients.Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II studyCabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma.Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialAxitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinomaRisks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysisFeasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.Biomarkers for tyrosine kinase inhibitors in renal cell cancer.Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.Tumor vasculature: the Achilles' heel of cancer?The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Clinical pharmacology of axitinib.Recent advances in the treatment of metastatic renal cell carcinoma.Axitinib for the treatment of advanced renal cell carcinoma.Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.Proteinuria with first-line therapy of metastatic renal cell cancer.Axitinib plasma pharmacokinetics and ethnic differences.A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.Axitinib: a review in advanced renal cell carcinoma.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients.Nephrotoxicity of anticancer treatment.Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.
P2860
Q24613720-E0F0B4D1-30FD-4AAC-8E38-A876B0AF7D83Q26751341-BB3FA464-195D-4789-9EDB-5E1E7E28B0B2Q26998017-01E35762-E55A-4C42-AFF3-FE0C5949B5F6Q31102468-FBE14C61-41A5-4788-AC52-8CAAA0E9E79CQ33555212-443AFDDF-04BB-45F4-ADC4-C16F4FCE9E65Q33633424-50BC6209-0EEB-4623-95FD-88B13ED9B29AQ33778275-DE70F757-1118-4A68-B988-8B8AB2DB766CQ33823247-3D327FF5-5271-4444-9A50-7F3999DED17AQ33931413-8E37401B-9969-444D-BD0D-498DEAC9166BQ33997879-9F22D4BC-38E9-4C88-A3EA-E736A1126C6EQ34245458-A98739DA-5E55-45DA-986C-F6BC496966D2Q34468729-41CF032C-975E-4B92-B760-D224BB307221Q35052037-11CB7468-9778-43AE-8B12-679BA90863C9Q35118673-995C6F90-10E3-4012-9EC3-EA2A06503BFDQ35562209-F7FB574B-DB0F-4F76-8725-0D3B981668CCQ36450612-8EAB09A6-586A-430C-9947-A9273F302E28Q36755620-CCF136A3-C858-4D45-8F6E-74CA8E629B63Q36876472-BF116318-3511-4EF1-B590-A21CEB43614FQ37161889-2F2D0553-7965-40F0-9D2B-6485F4C869A9Q37337031-73FA681E-6F02-4545-B192-462F87696587Q37387563-773E1E50-A13A-49E1-948A-B6EB6EDFA404Q38015387-F17C1514-30D2-44CA-B4BD-ECCCDDD95158Q38057420-2D41BB81-DD05-4533-8DFE-1490AF7C06D8Q38076349-A18B97FA-A437-4AF0-8502-598E4F964786Q38107175-185DC381-EFEB-4833-958D-1A5FD5571D16Q38108392-9D4FF8C6-A2E3-4542-B1B6-1E15F4345722Q38170397-6375C7DB-5E7E-48D2-966F-D6E9556EFCB8Q38196939-B9B89B78-57C1-4277-BD57-D34AD0BBAA04Q38287907-86E6C259-727A-4D66-A7C1-1A7C314C747FQ38348548-DBA532A4-56EA-4233-9360-FBE5EF0FCD3CQ38378485-25F5FA87-DFDC-4F1C-B616-5BA607D6015BQ38402997-F2F3B5AC-8098-4ABD-B728-7B3DD4AFB243Q38514440-B6916830-2652-46E0-8A0B-A10241A5303BQ38543085-14108071-8847-4182-8DB3-B14E39810C4FQ38612808-8BF6185C-09E3-461B-B2D4-F7BEE88FFBFDQ38657787-179F935C-AAA2-4C4E-B18A-E6F75B49CD52Q38982360-5410701E-1E1A-4240-9BC6-F0F0ADCD9A1BQ39198933-335A6883-07C5-4F87-8D3C-FE37584369F4Q41496075-5D85D5A3-19AF-48ED-B0E8-961E6F9C15F6Q43939236-BE6597CE-A8F0-44C8-86B2-2BC8BB8EBED7
P2860
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Key predictive factors of axit ...... tastatic renal cell Carcinoma.
@en
Key predictive factors of axitinib
@nl
type
label
Key predictive factors of axit ...... tastatic renal cell Carcinoma.
@en
Key predictive factors of axitinib
@nl
prefLabel
Key predictive factors of axit ...... tastatic renal cell Carcinoma.
@en
Key predictive factors of axitinib
@nl
P2093
P1476
Key predictive factors of axit ...... tastatic renal cell Carcinoma.
@en
P2093
Hayakazu Nakazawa
Hideyuki Akaza
Hiro-omi Kanayama
Hirotsugu Uemura
Hiroyuki Fujimoto
Japan Axitinib Phase II Study Group
Keiji Imai
Nobuo Shinohara
Seiichiro Ozono
Seiji Naito
P304
P356
10.1016/J.EJCA.2011.07.014
P577
2011-08-31T00:00:00Z